Douglas Plassche
Net Worth
Last updated:
What is Douglas Plassche net worth?
The estimated net worth of Mr. Douglas Plassche is at least $3,527,422 as of 27 Apr 2015. He owns shares worth $42,022 as insider and has received compensation worth at least $3,485,400 in Elite Pharmaceuticals, Inc..
What is the salary of Douglas Plassche?
Mr. Douglas Plassche salary is $348,540 per year as Executive Vice President of Operations in Elite Pharmaceuticals, Inc..
How old is Douglas Plassche?
Mr. Douglas Plassche is 61 years old, born in 1964.
What stocks does Douglas Plassche currently own?
As insider, Mr. Douglas Plassche owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Elite Pharmaceuticals, Inc. (ELTP) | Executive Vice President of Operations | 73,094 | $0.57 | $42,022 |
What does Elite Pharmaceuticals, Inc. do?
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
Douglas Plassche insider trading
Elite Pharmaceuticals, Inc.
Mr. Douglas Plassche has made only one insider trade in 2015, according to the Form 4 filled with the SEC. He sold 85,530 units of ELTP stock on 27 Apr 2015.
As of 27 Apr 2015 he still owns at least 73,094 units of ELTP stock.
Elite Pharmaceuticals key executives
Elite Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Mr. Douglas Plassche (61) Executive Vice President of Operations
- Mr. Nasrat Hakim (64) Chairman, Chief Executive Officer & Pres